Slc26a6‐null mice exhibit defects in intestinal oxalate secretion, resulting in enhanced net absorption of ingested oxalate, hyperoxalemia, hyperoxaluria and a high incidence of kidney stones [5, 6]. Here, SLC26A6 is linked to nephrolithiasis.